Stemina Biomarker Discovery announced today that its decTOX quickPredict (devTOXqP) screening platform was able to predict with high accuracy developmental toxicity in humans. The study, which published in the Toxicological Sciences, resulted from…
Stemina Biomarker Discovery’s recent study on cardiovascular toxicity was published in the Toxicological Sciences journal this month, the company announced recently. According to a release, the study suggests that the results…
NeuroPointDX, the diagnostics division of Stemina Biomarker Discover, has validated a first-generation autism diagnostic blood test panel in its Children’s Autism Metabolome Project (CAMP) clinical study, the organization announced recently….
Stemina Biomarker Discovery is preparing to go to market in early 2018 with its autism diagnostic test panel, the company announced recently. According to a release, Heiner Dreismann, the former head…
NeuroPointDX, the diagnostics division of Stemina Biomarker Discovery, and New York-based Ovid Therapeutics announced today they will team up to identify novel biomarkers of a rare genetic disorder called Angelman syndrome….
Stemina Biomarker Discovery Inc., is rebranding its diagnostics to more accurately represent its focus on neurological disorders, the company announced recently. According to a release, NeuroPointDX, a division of Stemina,…
Stemina Biomarker Discovery Inc., a company focused on diagnosis and individualized treatment of neurological disorders, received a $2.7 million grant from the National Institute of Mental Health (NIMH) to support the Children’s Autism…
The Nancy Lurie Marks Family Foundation is investing $2.3 million to support Stemina Biomarker Discovery‘s clinical study of biomarkers in the blood of children with autism spectrum disorders (ASD), the foundation…
Stemina Biomarker Discovery announced this week it received a five-year contract worth $10,637,000 from the U.S. Environmental Protection Agency (EPA) in conjunction with the federal agency’s ToxCast initiative. According to…
